文献速递临床试验与 GCP

艾司氯胺酮与舒芬太尼作为无痛胃肠镜镇静镇痛药的双盲随机对照试验

Esketamine versus sufentanil as analgesics for sedation during painless gastrointestinal endoscopy: a double-blinded randomized controlled trial.
PubMed 文献 · Trials · 2025-10-21

本研究纳入2022年11月至2023年4月行无痛胃肠镜的318例患者,按1:1随机分为0.1 µg/kg舒芬太尼组或0.15 mg/kg艾司氯胺酮组,两组均联合咪达唑仑和丙泊酚。与舒芬太尼组相比,艾司氯胺酮组低血压、呼吸抑制(呼吸暂停>30秒)和缺氧发生率降低,但可能增加咳嗽和分泌物增多。

要点

  • 艾司氯胺酮组低血压发生率12.8% vs 舒芬太尼组36.2%(P<0.001)。
  • 艾司氯胺酮组缺氧发生率7.1% vs 舒芬太尼组16.1%(P=0.018)。
  • 艾司氯胺酮可能增加咳嗽(P<0.001)和分泌物增多(P=0.032)。

核心结论

  • 艾司氯胺酮联合咪达唑仑和丙泊酚用于无痛胃肠镜可实现无阿片类镇静,并减少低血压和缺氧的发生。
  • 该方案的剂量尚需进一步探索,以避免咳嗽和分泌物增多。

研究设计与样本

  • 双盲随机对照试验,纳入2022年11月至2023年4月行无痛胃肠镜的患者318例,按1:1随机分为0.1 µg/kg舒芬太尼组或0.15 mg/kg艾司氯胺酮组。
  • 除镇痛药外,所有患者均给予咪达唑仑和丙泊酚。

主要发现

  • 与舒芬太尼组相比,艾司氯胺酮组低血压发生率降低(12.8% vs 36.2%,95% CI 13.20-33.09,P<0.001)。
  • 与舒芬太尼组相比,艾司氯胺酮组呼吸抑制(呼吸暂停>30秒)发生率降低(2.1% vs 15.4%,95% CI 6.47-20.52,P<0.001)。
  • 与舒芬太尼组相比,艾司氯胺酮组缺氧发生率降低(7.1% vs 16.1%,95% CI 1.07-16.92,P=0.018)。
  • 艾司氯胺酮组可能增加咳嗽发生率(P<0.001)和分泌物增多发生率(P=0.032)。
  • 两组检查和恢复时间无显著差异(P>0.05)。

局限性

  • 该方案的剂量尚需进一步探索,以避免咳嗽和分泌物增多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Most troubling of painless gastrointestinal endoscopy is hypoxia and hypotension. Esketamine has sympathomimetic and respiratory protection, which combined with midazolam and propofol may reduce these troubles. So, this study aims to explore the efficacy and safety of this regimen. METHODS: In total, 318 patients who received painless gastrointestinal endoscopy from November 2022 to April 2023 were included and randomly divided into two groups at 1:1: 0.1 µg/kg sufentanil (Suf) or 0.15 mg/kg esketamine (Esk) group. Except for analgesics, all patients were given midazolam and propofol. The incidence of hypotension and hypoxia (SPO2 < 93%) during the examination was observed. RESULTS: Compared with the Suf, the Esk group reduced the incidence of hypotension (12.8% vs 36.2%, 95% confidence interval (CI) 13.20-33.09, P < 0.001), respiratory depression (apnea > 30 s) (2.1% vs 15.4%, 6.47-20.52, P < 0.001), and hypoxia (7.1% vs 16.1%, 1.07-16.92, P = 0.018), but may increase the incidence of coughing (P < 0.001) and increased secretions (P = 0.032). There was no significant difference in the examination and recovery time (P > 0.05). CONCLUSION: Esketamine, midazolam, and propofol for painless gastrointestinal endoscopy can achieve opioid-free sedation and reduce the occurrence of hypotension and hypoxia. However, the dosages of this regimen need to be further explored to avoid coughing and increased secretions. TRIAL REGISTRATION: This study has been registered in the Chinese Clinical Trial Center ( https://www.chictr.org.cn/index.html , Date: November 3, 2022, No: ChiCTR2200065379).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li TT, He XL, Tang HL, et al. Esketamine versus sufentanil as analgesics for sedation during painless gastrointestinal endoscopy: a double-blinded randomized controlled trial. Trials. 2025. PMID: 41121399. doi:10.1186/s13063-025-09073-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。